NASDAQ: IMDX
Insight Molecular Diagnostics Inc Stock

$2.91-0.12 (-3.96%)
Updated Jul 8, 2025
IMDX Price
$2.91
Fair Value Price
N/A
Market Cap
$83.22M
52 Week Low
$1.92
52 Week High
$4.75
P/E
-0.75x
P/B
8.14x
P/S
20.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.84M
Earnings
-$58.26M
Gross Margin
52.6%
Operating Margin
-1,513.51%
Profit Margin
-1,516.1%
Debt to Equity
4.91
Operating Cash Flow
-$23M
Beta
1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

IMDX Overview

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine IMDX's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Diagnostic & Research

Industry Rating
C
IMDX
Ranked
Unranked of 43

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$47.85A
$15.59A
$99.27B
View Top Diagnostic & Research Stocks

Be the first to know about important IMDX news, forecast changes, insider trades & much more!

IMDX News

Overview

Due Diligence Score

Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IMDX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IMDX is poor value based on its book value relative to its share price (8.14x), compared to the US Diagnostics & Research industry average (3.62x)
P/B vs Industry Valuation
IMDX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IMDX due diligence checks available for Premium users.

Valuation

IMDX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.75x
Industry
20.59x
Market
30.75x

IMDX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
8.14x
Industry
3.62x
IMDX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IMDX's financial health

Profit margin

Revenue
$2.1M
Net Income
-$6.7M
Profit Margin
-312%
IMDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IMDX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$60.4M
Liabilities
$50.1M
Debt to equity
4.91
IMDX's short-term assets ($36.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMDX's long-term liabilities ($40.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMDX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IMDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.9M
Investing
-$307.0k
Financing
$28.6M
IMDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IMDX vs Diagnostic & Research Stocks

TickerZen RatingMarket Cap1d %P/EP/B
IMDX$83.22M-3.96%-0.75x8.14x
VNRX$73.15M+5.50%-2.63x-2.63x
NOTVC$72.83M+3.41%-0.66x0.46x
SERAC$102.47M+12.40%-2.89x1.08x
FONRA$102.68M+0.84%12.28x0.60x

Insight Molecular Diagnostics Stock FAQ

What is Insight Molecular Diagnostics's quote symbol?

(NASDAQ: IMDX) Insight Molecular Diagnostics trades on the NASDAQ under the ticker symbol IMDX. Insight Molecular Diagnostics stock quotes can also be displayed as NASDAQ: IMDX.

If you're new to stock investing, here's how to buy Insight Molecular Diagnostics stock.

What is the 52 week high and low for Insight Molecular Diagnostics (NASDAQ: IMDX)?

(NASDAQ: IMDX) Insight Molecular Diagnostics's 52-week high was $4.75, and its 52-week low was $1.92. It is currently -38.74% from its 52-week high and 51.4% from its 52-week low.

How much is Insight Molecular Diagnostics stock worth today?

(NASDAQ: IMDX) Insight Molecular Diagnostics currently has 28,599,285 outstanding shares. With Insight Molecular Diagnostics stock trading at $2.91 per share, the total value of Insight Molecular Diagnostics stock (market capitalization) is $83.22M.

Insight Molecular Diagnostics stock was originally listed at a price of $180.00 in Jan 4, 2016. If you had invested in Insight Molecular Diagnostics stock at $180.00, your return over the last 9 years would have been -98.38%, for an annualized return of -36.76% (not including any dividends or dividend reinvestments).

How much is Insight Molecular Diagnostics's stock price per share?

(NASDAQ: IMDX) Insight Molecular Diagnostics stock price per share is $2.91 today (as of Jul 8, 2025).

What is Insight Molecular Diagnostics's Market Cap?

(NASDAQ: IMDX) Insight Molecular Diagnostics's market cap is $83.22M, as of Jul 9, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Insight Molecular Diagnostics's market cap is calculated by multiplying IMDX's current stock price of $2.91 by IMDX's total outstanding shares of 28,599,285.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.